Literature DB >> 3612950

Two distinct sequence elements mediate retroviral gene expression in embryonal carcinoma cells.

H Weiher, E Barklis, W Ostertag, R Jaenisch.   

Abstract

Moloney murine leukemia virus (M-MuLV) and M-MuLV-derived retroviral vectors are not expressed in early mouse embryos or in embryonal carcinoma cells. M-MuLV-derived mutants or M-MuLV-related variants which transduce the neomycin phosphotransferase gene can, however, induce drug resistance in embryonal carcinoma cells with high efficiency. In this study we investigated the sequences critical for retroviral gene expression in two different embryonal carcinoma cell lines, F9 and PCC4. We show that two synergistically acting sequence elements mediate expression in embryonal carcinoma cells. One of these is located within the U3 region of the viral long terminal repeat, and the second one is in the 5' untranslated region of the retrovirus. The latter element, characterized by a single point mutation, affects the level of stable RNA in infected cells, suggesting a regulatory mechanism similar to that of human immunodeficiency virus in human T cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612950      PMCID: PMC255781     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Non-function of a Moloney murine leukaemia virus regulatory sequence in F9 embryonal carcinoma cells.

Authors:  E Linney; B Davis; J Overhauser; E Chao; H Fan
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

2.  New M13 vectors for cloning.

Authors:  J Messing
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

3.  De novo methylation, expression, and infectivity of retroviral genomes introduced into embryonal carcinoma cells.

Authors:  C L Stewart; H Stuhlmann; D Jähner; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

4.  Silent infection of murine embryonal carcinoma cells by Moloney murine leukemia virus.

Authors:  W C Speers; J W Gautsch; F J Dixon
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

5.  Regulation of simian virus 40 transcription: sensitive analysis of the RNA species present early in infections by virus or viral DNA.

Authors:  B A Parker; G R Stark
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

6.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

7.  Myeloproliferative virus, a cloned murine sarcoma virus with spleen focus-forming properties in adult mice.

Authors:  W Ostertag; K Vehmeyer; B Fagg; I B Pragnell; W Paetz; M C Le Bousse; F Smadja-Joffe; B Klein; C Jasmin; H Eisen
Journal:  J Virol       Date:  1980-02       Impact factor: 5.103

8.  De novo methylation and expression of retroviral genomes during mouse embryogenesis.

Authors:  D Jähner; H Stuhlmann; C L Stewart; K Harbers; J Löhler; I Simon; R Jaenisch
Journal:  Nature       Date:  1982-08-12       Impact factor: 49.962

9.  Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus.

Authors:  R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

10.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06
View more
  39 in total

1.  The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites.

Authors:  S Rivella; J A Callegari; C May; C W Tan; M Sadelain
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Lack of shielding of primer binding site silencer-mediated repression of an internal promoter in a retrovirus vector by the putative insulators scs, BEAD-1, and HS4.

Authors:  C Modin; F S Pedersen; M Duch
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro.

Authors:  I Hamaguchi; N B Woods; I Panagopoulos; E Andersson; H Mikkola; C Fahlman; R Zufferey; L Carlsson; D Trono; S Karlsson
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells.

Authors:  P Soriano; G Friedrich; P Lawinger
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  The R-U5-5' leader sequence of neurovirulent wild mouse retrovirus contains an element controlling the incubation period of neurodegenerative disease.

Authors:  J L Portis; S Perryman; F J McAtee
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Analysis of the binding proteins and activity of the long terminal repeat of Moloney murine leukemia virus during differentiation of mouse embryonal carcinoma cells.

Authors:  T Tsukiyama; O Niwa; K Yokoro
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  Optimized transduction of canine paediatric CD34(+) cells using an MSCV-based bicistronic vector.

Authors:  S E Suter; T A Gouthro; P A McSweeney; R A Nash; M E Haskins; P J Felsburg; P S Henthorn
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

8.  Two blocks in Moloney murine leukemia virus expression in undifferentiated F9 embryonal carcinoma cells as determined by transient expression assays.

Authors:  G Feuer; M Taketo; R C Hanecak; H Fan
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

9.  Derivatives of Moloney murine sarcoma virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional Sp1 binding site.

Authors:  V E Prince; P W Rigby
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

10.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.